Wedbush Analysts Raise Earnings Estimates for XOMA Corp (XOMA)
XOMA Corp (NASDAQ:XOMA) – Investment analysts at Wedbush boosted their Q1 2019 EPS estimates for XOMA in a report issued on Tuesday, April 16th. Wedbush analyst L. Moussatos now expects that the biotechnology company will earn $0.04 per share for the quarter, up from their prior forecast of ($0.58). Wedbush has a “Buy” rating and a $26.00 price objective on the stock. Wedbush also issued estimates for XOMA’s Q2 2019 earnings at ($1.29) EPS, FY2019 earnings at ($1.75) EPS, FY2021 earnings at ($2.06) EPS and FY2023 earnings at ($0.34) EPS.
XOMA has been the subject of several other reports. ValuEngine downgraded XOMA from a “hold” rating to a “sell” rating in a research report on Wednesday, January 2nd. Zacks Investment Research upgraded XOMA from a “sell” rating to a “hold” rating in a report on Saturday, March 9th. Finally, HC Wainwright set a $30.00 price target on XOMA and gave the company a “buy” rating in a report on Friday, April 12th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. XOMA has an average rating of “Hold” and an average target price of $24.82.
XOMA (NASDAQ:XOMA) last issued its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.14. XOMA had a negative return on equity of 175.48% and a negative net margin of 251.80%. The firm had revenue of $1.69 million during the quarter, compared to the consensus estimate of $1.30 million.
A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. raised its holdings in XOMA by 12.4% in the 4th quarter. BlackRock Inc. now owns 508,672 shares of the biotechnology company’s stock valued at $6,434,000 after acquiring an additional 56,130 shares during the last quarter. Opaleye Management Inc. raised its holdings in XOMA by 25.0% in the 4th quarter. Opaleye Management Inc. now owns 400,000 shares of the biotechnology company’s stock valued at $5,060,000 after acquiring an additional 80,000 shares during the last quarter. Fosun International Ltd acquired a new position in XOMA in the 4th quarter valued at $3,842,000. Vanguard Group Inc. raised its holdings in XOMA by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 311,093 shares of the biotechnology company’s stock valued at $5,466,000 after acquiring an additional 3,167 shares during the last quarter. Finally, Vanguard Group Inc raised its holdings in XOMA by 1.0% in the 3rd quarter. Vanguard Group Inc now owns 311,093 shares of the biotechnology company’s stock valued at $5,466,000 after acquiring an additional 3,167 shares during the last quarter. Institutional investors own 48.00% of the company’s stock.
XOMA Company Profile
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.
Recommended Story: How can you know how many shares are floating?
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.